Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2014 16:01 ET | Source: TESARO, Inc.

TESARO Appoints Tim Pearson as Chief Financial Officer

WALTHAM, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Tim Pearson as Chief Financial Officer....
May 27, 2014 08:00 ET | Source: TESARO, Inc.

TESARO Announces Webcast of Investor & Analyst Briefing at ASCO

WALTHAM, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, invites investors and the general public to listen to a webcast of an...
May 16, 2014 09:26 ET | Source: TESARO, Inc.

TESARO Announces Election of Earl M. (Duke) Collier, Jr. to Board of Directors and Results of Annual Stockholder Meeting

WALTHAM, Mass., May 16, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Earl M. (Duke) Collier, Jr. has been elected to the...
May 14, 2014 17:48 ET | Source: TESARO, Inc.

TESARO Announces Six Abstracts to be Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2014 American...
May 14, 2014 08:00 ET | Source: TESARO, Inc.

TESARO to Present at the UBS 2014 Global Healthcare Conference

WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Dr. Mary Lynne Hedley, president of TESARO, will present at the UBS...
May 12, 2014 07:30 ET | Source: TESARO, Inc.

TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant

Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of Chemotherapy Achieved Key Secondary Endpoints of CR in the Acute and...
May 01, 2014 08:01 ET | Source: TESARO, Inc.

TESARO to Present at the Deutsche Bank Securities 39th Annual Health Care Conference

WALTHAM, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Dr. Mary Lynne Hedley, President of TESARO, will present at the...
April 30, 2014 16:01 ET | Source: TESARO, Inc.

TESARO Announces First-Quarter 2014 Operating Results

Oral Rolapitant New Drug Application on Track for Submission to U.S. FDA in Mid-2014 Multiple Data Presentations Planned for the 2014 ASCO Meeting Niraparib Phase 3 BRAVO and NOVA Trials...
April 16, 2014 16:01 ET | Source: TESARO, Inc.

TESARO to Announce First Quarter 2014 Financial Results on April 30, 2014

WALTHAM, Mass., April 16, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2014 financial results on Wednesday, April 30, 2014, after the close of the U.S. financial...
April 02, 2014 08:01 ET | Source: TESARO, Inc.

TESARO Announces Data Presentations At 2014 AACR Annual Meeting

WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and...